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INTRODUCTION
Multiple chemical sensitivity (MCS) is defined as “an acquired
disorder characterized by recurrent symptoms, referable to multi-
ple organ systems, occurring in response to demonstrable expo-
sure to many chemically unrelated compounds at doses below
those established in the general population to cause harmful ef-
fects” (1). The definition differentiates MCS from allergic or toxi-
cologic diseases, which were previously candidates as the cause of
MCS. To screen and study the complicated profile of MCS pa-
tients, a questionnaire was established, called the Quick Environ-
ment Exposure Sensitivity Inventory (QEESI), which remains the
gold standard for MCS diagnosis (2). Currently, MCS symptoms
cannot be explained fully based on the general medical condition or
the direct effect of a substance (3, 4). Many clinicians accept that a
diagnosis of somatic symptoms disorder (SSD) is an appropriate
diagnostic category for MCS (3). A pathophysiological hypothesis
has been proposed for MCS. Exogenous toxic exposures cause
toxicant- induced loss of tolerance with dysregulation of immune
state (5), which may involve N-methyl -D-aspartate (NMDA) sen-
sitization with increased level of nitric oxide (NO) and peroxyni-
trite (5). No medication has been found to be effective for the
treatment of MCS(3).
Levetiracetam is an antiepileptic agent which reduces the re-
lease of presynaptic neurotransmitter, including glutamate, by
binding to a presynaptic vesicle protein (6). The mechanisms are
paradoxical ; the amplitudes of the late postsynaptic field potentials
are decreased for hyperactive synapses, with minimal effect on
normal synaptic transmission (7). Recent studies also showed that
levetiracetam has antioxidant property (8, 9), and inhibits NO level
(10).
We treated a patient with MCS with levetiracetam administration
based on a diagnosis of epilepsy. We found that levetiracetam
medication eliminated multiple symptoms induced by exposure to
chemicals. This preliminary report of this curious phenomenon
proposes further investigation.
CASE REPORT
A 23-year-old female with uneventful birth and normal develop-
ment. Ever since she was old enough to talk, she had complained of
multiple symptoms induced by several causative agents as shown
in Table 1, based on the QEESI (2), which was retrospectively
confirmed at age of 20. Symptoms of musculoskeletal, airway or
mucous membrane, heart/chest-related, gastrointestinal, cogni-
tive, affective, neuromuscular, head-related, and skin-related were
triggered by exposure to diesel or gas engine exhaust, tobacco
smoke, insecticide, gasoline, paint or paint thinner, cleaning prod-
ucts, fragrances, tar or asphalt, nailpolish or hairspray, and new
furnishings. Additionally, the patient also reported either increase
or decrease of body temperature with exposure to paint or paint
thinner, cleaning products, fragrances, tar or asphalt, nail polish or
hairspray, and new furnishings. Gastrointestinal, cognitive, and
skin-related symptoms could be precipitated by food intake. The
patient and her parents speculated these symptoms were probably
due to inclusion of agricultural chemicals and/or chemical season-
ings. Retrospectively, her mother thought that the patient’s MCS
had started at the age of 1year as gastrointestinal symptoms and/or
change in body temperature induced by the smell or ingestion of
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causative chemicals. Her symptoms fulfilled the diagnostic criteria
of MCS (1). She started to suffer partial seizures from the age of 17
years. The seizures started with unpleasant feeling followed by
visualillusions with raresecondary generalization. Physical exami-
nation found no abnormalities. Ictal electroencephalography clari-
fied that the seizures originated from the right parietal region.
Magnetic resonance (MR) imaging detected no abnormalities.
Levetiracetam (250 mg/day) administration was started under a
diagnosis of right parietal lobe epilepsy. Her multiple MCS symp-
toms disappeared completely within 2 days of starting levetiracetam
medication despite continuous exposure to the sensitizers. Three
months later, transient cessation of levetiracetam administration
resulted in recurrence of abdominal pain and headache. Resump-
tion of levetiracetam medication resulted in freedom from MCS
symptoms, which has continued for over 3 years with residual
epileptic seizures. The clinical course of the case is shown in Fig.1.
DISCUSSION
The present case showed that levetiracetam administration can
improve recurrent MCS symptoms. Our experience may indicate
that MCS involves a pathophysiological abnormality which can be
reduced by levetiracetam. The underlying etiology of MCS may
Table 1. Detailed relationship between the precipitating factors and presenting multiple chemical sensitivity (MCS) symptoms of Case 1
Precipitating
agents(Q1 of
QEESI)
Type of
exposure
MCS symptoms (Q3 of QEESI) ifexposed without LEV
1.Musculo
skeletal
2.Airway
or mucous
membrane
3.Heart/
chest-
related
4.Gastro-
intestinal
5.Cognitive 6.Affective 7.Neuro
muscular
8.Head-
related
9.Skin-
related
10.Genito-
urinary
Miscellaneous
1.Diesel or gas
engine exhaust
Olfactory N N Y Y Y N N Y Y N Insomnia
2.Tobacco
smoke
Olfactory N N N Y Y N N Y N N Insomnia
3. Insecticide Olfactory N N N Y N N N Y N N
4.Gasoline Olfactory N N Y Y Y N N Y Y N Insomnia
5.Paint or paint
thinner
Olfactory Y Y Y Y Y N Y Y Y N Increased BT
6.Cleaning
products
Olfactory Y N N Y Y Y Y Y Y N Decreased BT/
Insomnia
7.Fragrances Olfactory Y Y Y Y Y Y Y Y Y N Increased or
decreased BT,
Insomnia
8.Tar or asphalt Olfactory Y Y N Y Y N Y Y Y N Increased BT
9.Nail polish or
hairspray
Olfactory N N N Y Y N N Y Y N Increased or
decreased BT,
Insomnia
10.New
furnishings
Olfactory N N N Y Y N N Y Y N Increased BT
Precipitating agents for MCS symptoms are listed from Q1 of the Quick Environment Exposure Sensitivity Inventory (QEESI). Occurrence of MCS
symptoms, from Q3 of QEESI, are shown with/without levetiracetam (LEV). Note that 1) various MCS symptoms appear with multiple chemical
agents without LEV, and 2) all symptoms disappear with administration of LEV. BT, body temperature ; Y, yes ; N, no.
Fig. 1. Clinical course of the case. Arrow indicates the present point. Levetiracetam (LEV) administration eliminated multiple chemical sensitivity
(MCS) symptoms. CBZ, carbamazepine ; CLB, clobazam ; LTG, lamotrigine.
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involve NMDA sensitization as a vicious cycle of hypersensitive
NMDA receptors and elevation of NO, peroxynitrite (11). Chemi-
cals first activate the NMDA receptors, which raises levels of NO
and peroxynitrite. NO facilitates the release of neurotransmitters,
including glutamate as a retrograde messenger, which further
stimulate the NMDA receptors (11). Under this hypothesis, leveti-
racetam administration may act by releasing NMDA sensitization
through reducing excessive glutamate release as well as the anti-
oxidant property (8, 9), thus inhibiting the NO level (10). We
suggest that levetiracetam administration may be helpful for reliev-
ing MCS symptoms in a subset of patients. Levetiracetam admini-
stration has been reported as effective for SSD, although the
mechanism is still unknown (12). A recent MR spectroscopy study
clarified the presence of glutamatergic overactivation in somatiza-
tion disorder, a form of SSD (13). These studies may indicate that a
subset of SSD cases have glutamatergic overactivation, which
levetiracetam can normalize. The clinical significance of this obser-
vation is limited to this single case. A double-blind study is re-
quired to clarify the activity of levetiracetam for MCS.
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